Erdosteine prevents bleomycin-induced pulmonary fibrosis in rats


Söğüt S., Özyurt H., Armutçu F., Kart L., Iraz M., Akyol Ö., et al.

EUROPEAN JOURNAL OF PHARMACOLOGY, cilt.494, ss.213-220, 2004 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 494
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1016/j.ejphar.2004.04.045
  • Dergi Adı: EUROPEAN JOURNAL OF PHARMACOLOGY
  • Sayfa Sayısı: ss.213-220

Özet

Oxidative stress plays an important role in the pathogenesis of idiopathic pulmonary fibrosis. Therefore, erdosteine, an antioxidant, is expected to have an inhibitor potential against the disease. Rats were given one dose of bleomycin in pulmonary fibrosis groups and saline in controls. The first dose of oral erdosteine (10 mg/kg/day) was given 2 days before the bleomycin injection to achieve the plateau level in blood and continued until killing. At day 14, fibrotic changes were evaluated, using Aschoft's criteria and lung hydroxyproline content. Bleomycin produced a fivefold increase in fibrosis score that was decreased by 87% by erdosteine (P>0.001) and almost twofold increases in hydroxyproline content which were completely prevented by erdosteine. Myeloperoxidase activities and MDA levels, which were significantly higher in the bleomycin group, were then significantly attenuated by erdosteine. These results revealed that oral erdosteine may prevent the development of acute pulmonary inflammation caused by bleomycin injection via the repression of neutrophil accumulation and lipid peroxidation, resulting in the inhibition of subsequent lung fibrosis. (C) 2004 Elsevier B.V. All rights reserved.